Is the ASX Biotech Sector Seeing a Shift with Immutep's Lung Cancer Trial Progress?

2 min read | May 15, 2025 04:13 PM AEST | By Team Kalkine Media

Google News:

Is the ASX Biotech Sector Seeing a Shift with Immutep's Lung Cancer Trial Progress? — Image source: Shutterstock

Recent News

Zip Shares Push Higher as Market Watches Key Turning Point

Could These Under-the-Radar ASX Stocks Be Worth Watching?

ASX 200 Soars as Trump Signals Surprise Iran Peace Shift

Which ASX Small Caps Are Making Early Moves Today?

Make Kalkine Media
My Trusted Source

Highlights

Immutep (IMM) reports a major development in a lung cancer clinical trial

INSIGHT-003 trial evaluates eftilagimod alpha (efti) combined with Keytruda and chemotherapy

Conducted across multiple German research centres, including the Frankfurt Institute

The biotechnology sector, represented within indexes such as the ASX All Ordinaries and ASX 300, includes research-driven companies focusing on therapies across various medical fields. Immutep (ASX:IMM) operates in this sector with a focus on immuno-oncology. Its clinical pipeline involves drug candidates targeting cancer indications, including non-small cell lung cancer (NSCLC).

Clinical Trial Overview

Immutep (ASX:IMM) recently reported key findings from the INSIGHT-003 trial, a study evaluating eftilagimod alpha (efti) in combination with Keytruda and chemotherapy. This trial is not sponsored by the company but is being conducted independently by the Frankfurt Institute of Clinical Cancer Research and other German institutions. The study targets first-line treatment for advanced non-small cell lung cancer.

Eftilagimod Alpha and Keytruda Combination

The trial investigates the combination of eftilagimod alpha, an immunotherapy candidate, with the checkpoint inhibitor Keytruda. Eftilagimod alpha functions as a LAG-3 immunotherapeutic agent and is designed to activate antigen-presenting cells. The combination is used with standard chemotherapy, following protocols for treating patients with advanced lung cancer. According to the reporting from the research centres, the therapy demonstrated measurable clinical outcomes.

Independent Study Collaboration

The INSIGHT-003 study is part of a broader investigator-initiated clinical program. Its structure involves a collaboration between multiple German oncology centres. These sites are responsible for trial design, execution, and patient monitoring. The trial’s multi-centre design ensures data is collected across a diverse patient population, strengthening its clinical framework.

Position within the ASX Healthcare Landscape

Immutep (ASX:IMM), through its involvement in immunotherapy research, remains active in the healthcare component of the ASX indexes. The company's participation in global research collaborations highlights its role in advancing treatment pathways in oncology. Results from the INSIGHT-003 trial add to the ongoing documentation of clinical activity within the sector and underscore the role of investigator-led trials in shaping biotechnology progress.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.